DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

International Urology Cancer Summit made the following post on X:

“Non-BRCA1/2 HRR mutations might benefit from PARP inhibitors when direct BRCA complex interaction. Intriguing the effectiveness of platinum across all cohorts.”

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

Authors: Laura S. Graham, MD, Nicholas C. Henderson, Olesia Kellezi, BS, Clara Hwang, MD, Pedro C. Barata, MD, Mehmet A. Bilen, MD, Deepak Kilari, MD, Michael Pierro, MD, Bicky Thapa, MD, Abhishek Tripathi, MD, George Mo, MD, Matthew Labriola, MD, Joseph J. Park, MD, Shoshana Rothstein, MD, Rohan Garje, MD, Vadim S. Koshkin, MD, Vaibhav G. Patel, MD, Tanya Dorff, MD, Andrew J. Armstrong, MD, Rana R. McKay, MD, Ajjai Alva, MD and Michael T. Schweizer, MD

Source: International Urology Cancer Summit/X